Latest news with #PACB
Yahoo
03-07-2025
- Business
- Yahoo
Pacific Biosciences Targets Profitability by 2027 With Record Consumables Revenue
Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) delivered a presentation at the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 11. The company discussed its financial performance, highlighting both market limitations and growth prospects, and emphasized the promise of its long-read sequencing technology. Financially speaking, Pacific Biosciences of California (NASDAQ:PACB) reported that its consumable revenue in Q1 2025 reached a record $20.1 million, a 26% increase from the previous year. Additionally, by improving its gross margin, cutting operational costs, and increasing top-line growth, the company targets profitability by 2027. Pacific Biosciences of California (NASDAQ:PACB) is a biotech company that focuses on advanced genomic technologies, such as whole-genome sequencing, target sequencing, RNA sequencing, and epigenetics. By using its PacBio Sequel System, the company also developed a novel enrichment method for targeted SMRT sequencing. This greatly improves sequencing efficiency by using the CRISPR-Cas9 system to do away with the necessity for PCR amplification. While we acknowledge the potential of PACB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
PacBio Stock Slips Despite New China Distribution Deal With Haorui
PacBio PACB recently announced a key distribution agreement with Haorui Gene, a globally recognized leader in blood typing genomics. This strategic partnership grants PacBio access to a wider clinical laboratory network across China, accelerating the adoption of its HiFi sequencing technology. Haorui Gene, known for its expertise in genomic solutions and extensive reach within the clinical diagnostics ecosystem, will serve as an important channel partner to promote PacBio's advanced long-read sequencing platforms. Through this collaboration, PacBio aims to meet the growing demand for high-accuracy genomic sequencing in China, particularly in clinical research and precision medicine applications. By leveraging Haorui Gene's distribution capabilities and relationships with top-tier laboratories, PacBio is well-positioned to support more comprehensive and precise genomic analysis. Following the announcement, shares of the company closed flat at $1.12 on Friday. In the year-to-date period, PACB's shares have lost 48.6% compared with the industry's 9.7% decline. The S&P 500 decreased 1.2% in the same time frame. The deal with Haorui Gene positions PacBio for long-term growth by expanding its reach into China's vast clinical diagnostics market, enabling broader adoption of its HiFi sequencing technology. Through Haorui's extensive lab network, PacBio can drive recurring revenue from consumables and services while accelerating its footprint in one of the world's largest genomics markets. This strategic move not only boosts technology adoption but also strengthens PacBio's role in advancing precision medicine across Asia, laying the groundwork for future partnerships and population-scale initiatives. Meanwhile, PACB currently has a market capitalization of $294.4 million. The company expects its earnings to grow 16.8% in 2025. Image Source: Zacks Investment Research PacBio's newly formalized distribution agreement with Haorui Gene is focused on accelerating the adoption of HiFi long-read sequencing technology across clinical and research settings in China, particularly in transfusion medicine and hematology. These are fields where comprehensive, accurate genomic data is vital to improving patient outcomes. The partnership is designed to make PacBio's HiFi sequencing the preferred solution for analyzing highly polymorphic genomic regions, structural variants, and full-length genes, areas critical for safe blood transfusions, precise donor-recipient matching, and the identification of rare blood types. Haorui Gene, founded in 2020, has rapidly emerged as a leader in blood typing genomics in China. The company operates seven Sequel II and three Revio systems to support national initiatives in HLA typing, blood group genotyping, and rare blood type discovery. Through its work, Haorui has demonstrated that long-read sequencing can provide unparalleled resolution in genomically complex regions, surpassing the capabilities of traditional short-read technologies. The company has already contributed to over 20 peer-reviewed publications and has seen widespread adoption of its approaches across Chinese blood centers, establishing itself as a trusted player in precision hematology. Under the agreement, Haorui Gene will likely distribute PacBio's full product suite, including the Vega platform, delivering comprehensive, end-to-end solutions for clinical labs, genomics institutions, and blood centers. This supports national initiatives like erythrocyte antigen mapping and rare blood type classification, which require high-resolution, allele-level insights. Haorui's rollout of HiFi-based HLA typing in 2022 and blood group panels in 2023 highlights growing momentum in long-read sequencing. The partnership aims to scale access to PacBio's technology and establish it as a cornerstone of personalized medicine and clinical diagnostics in China's rapidly expanding genomics market. Per a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is expected to witness a CAGR of 20.12% from 2025 to 2030. The major factors driving the market growth include the rising prevalence of genetic diseases, such as cancers and chromosomal disorders, the rising popularity of personalized medicine, and rising technological advancements resulting in the emergence of newer technologies, such as third-generation sequencing. PACB carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
1 Russell 2000 Stock with Exciting Potential and 2 to Approach with Caution
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial. The high-risk, high-reward nature of the Russell 2000 makes stock selection critical, and we're here to guide you toward the right ones. Keeping that in mind, here is one Russell 2000 stock that could be the next big thing and two best left off your watchlist. Market Cap: $343.1 million Started as a small grocery store in New York City, B&G Foods (NYSE:BGS) is an American packaged foods company with a diverse portfolio of more than 50 brands. Why Should You Dump BGS? Products have few die-hard fans as sales have declined by 3.3% annually over the last three years Performance over the past three years shows each sale was less profitable as its earnings per share dropped by 30.7% annually, worse than its revenue 7× net-debt-to-EBITDA ratio shows it's overleveraged and increases the probability of shareholder dilution if things turn unexpectedly B&G Foods's stock price of $4.38 implies a valuation ratio of 6.1x forward P/E. If you're considering BGS for your portfolio, see our FREE research report to learn more. Market Cap: $345.1 million Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. Why Do We Pass on PACB? 6.6% annual revenue growth over the last two years was slower than its healthcare peers Free cash flow margin dropped by 29.1 percentage points over the last five years, implying the company became more capital intensive as competition picked up Short cash runway increases the probability of a capital raise that dilutes existing shareholders At $1.13 per share, PacBio trades at 2.1x forward price-to-sales. Read our free research report to see why you should think twice about including PACB in your portfolio, it's free. Market Cap: $2.59 billion Founded by PayPal alumni Jeremy Stoppelman and Russel Simmons, Yelp (NYSE:YELP) is an online platform that helps people discover local businesses through crowd-sourced reviews. Why Are We Positive On YELP? Platform is difficult to replicate at scale and results in a best-in-class gross margin of 91.2% Highly efficient business model is illustrated by its impressive 25.7% EBITDA margin, and its rise over the last few years was fueled by some leverage on its fixed costs Share repurchases have amplified shareholder returns as its annual earnings per share growth of 24.7% exceeded its revenue gains over the last three years Yelp is trading at $40.25 per share, or 7.5x forward EV/EBITDA. Is now the right time to buy? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Yahoo
13-05-2025
- Business
- Yahoo
PACB Stock May Rise Following the Deal With Chulalongkorn University
PacBio PACB recently announced a strategic collaboration with Chulalongkorn University, one of Thailand's foremost institutions in genomic and translational research, to implement PacBio's HiFi whole genome sequencing (WGS) as part of the newborn screening research program. This initiative marks the first population-scale deployment of PacBio's HiFi technology in the Asia Pacific region. It is designed to evaluate how comprehensive genomic data can enable earlier and more accurate identification of rare, treatable conditions in newborns. By integrating PacBio's advanced long-read sequencing capabilities, the program will help uncover a broader spectrum of genetic variants that often go undetected with traditional screening methods. Through this effort, PacBio and Chulalongkorn University aim to build a scalable model that could transform early-stage diagnostics and public health planning on a global scale. Following the announcement, shares of the company closed flat at $1.12 on Friday. In the year-to-date period, PACB's shares have lost 38.8% compared with the industry's 10.1% decline. The S&P 500 decreased 4.4% in the same time frame. This collaboration positions PacBio at the forefront of a major shift in global healthcare, signaling growing adoption of its HiFi sequencing technology for large-scale clinical applications. By demonstrating real-world utility in a critical use case, such as newborn screening, PacBio not only expands its footprint in the fast-growing Asia Pacific region but also builds a compelling case for broader international adoption. Successful implementation could lead to long-term revenue growth from government contracts, public health partnerships, and increased demand for HiFi systems, reinforcing investors' confidence in the scalability and relevance of PacBio's platform in precision medicine. Meanwhile, PACB currently has a market capitalization of $336.1 million. The company expects its earnings to grow 13.1% in 2025. Image Source: Zacks Investment Research The collaboration between PacBio and Chulalongkorn University is a landmark initiative that highlights the transformative potential of WGS in public health. Traditional newborn screening programs typically rely on targeted panels to detect a limited number of conditions, often missing rare or complex genetic disorders. PacBio's HiFi WGS, by contrast, delivers highly accurate, long-read genomic data that captures regions of the genome inaccessible to short-read technologies. This includes structural variants, repeat expansions, and epigenomic information, all of which are critical for identifying a wider spectrum of genetic risks from birth. By enabling a more complete and precise view of the newborn genome, the technology opens the door to earlier diagnosis and intervention for conditions that might otherwise remain undetected until much later in life. Chulalongkorn University, through its Center of Excellence for Medical Genomics, is likely to bring deep expertise and infrastructure to the table, making it an ideal partner for this endeavor. The university aims to build a robust and scalable research model that can be replicated across other national health systems. This research-driven approach not only enhances clinical care but also contributes to public health data systems, laying the groundwork for informed policy decisions, better resource allocation, and eventually, personalized healthcare strategies on a national scale. On a broader level, this initiative positions Thailand as a leader in precision medicine within the Asia Pacific region and places PacBio at the center of a growing global movement toward genome-informed healthcare. By successfully deploying HiFi WGS in a population-scale screening program, PacBio is setting a benchmark for how advanced sequencing technologies can be integrated into public health. This could catalyze similar initiatives in other countries, unlocking new markets and reinforcing PacBio's reputation as a pioneer in genomic innovation. With increasing recognition of genomics as a foundational tool in early disease detection and prevention, this collaboration not only accelerates scientific progress but also enhances PacBio's long-term commercial and strategic outlook. Per a report by Grand View Research, the global whole genome sequencing market size was estimated at $2.12 billion in 2024 and is expected to witness a CAGR of 22.17% from 2025 to 2030. The WGS market is experiencing significant growth, driven by a confluence of technological advancements, decreasing costs, and a growing demand for personalized medicine. Several key factors contribute to this expansion, transforming the landscape of genomics and impacting various sectors, including healthcare, research, and agriculture. PACB carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. CVS Health has a long-term estimated growth rate of 11.4%. CVS's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 13.3%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
